Citations |
Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity. Yang Y, et al . Mol Biosyst. 2012 Sep 18. PMID: 22990663 . Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Wunderlich A, et al . Endocrine. 2012 Apr 5. PMID: 22477151 . MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Moretti L, et al . Int J Radiat Oncol Biol Phys. 2011 Jul 15,80(4):1189-97. PMID: 21514073 . Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Chakravarty A, et al . Cancer Res. 2011 Feb 1,71(3):675-85. PMID: 21148750 . Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Macarulla T, et al . Mol Cancer Ther. 2010 Oct,9(10):2844-52. PMID: 20724522 . Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. Sloane DA, et al . ACS Chem Biol. 2010 Jun 18,5(6):563-76. PMID: 20426425 . MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Huck JJ, et al . Mol Cancer Res. 2010 Mar,8(3):373-84. PMID: 20197380 . |